Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Passamonti, Francesco, Prof, Griesshammer, Martin, Prof, Palandri, Francesca, MD, Egyed, Miklos, Prof, Benevolo, Giulia, MD, Devos, Timothy, Prof, Callum, Jeannie, FRCPC, Vannucchi, Alessandro M, Prof, Sivgin, Serdar, MD, Bensasson, Caroline, PhD, Khan, Mahmudul, PhD, Mounedji, Nadjat, MD, Saydam, Guray, Prof
Published in The lancet oncology (2017)
Published in The lancet oncology (2017)
Get full text
Journal Article